Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Frequently asked questions
What sector does Autolus Therapeutics plc (AUTL) operate in?
Autolus Therapeutics plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Autolus Therapeutics plc (AUTL) current stock price?
As of the latest data, Autolus Therapeutics plc stock price is $2.40, with a previous close of $2.34. Autolus Therapeutics plc gained $0.06 in the last trading session, representing a 2.35% increase.
What is Autolus Therapeutics plc (AUTL) current market capitalization?
Autolus Therapeutics plc market cap is approximately 637.41 million.
What is Autolus Therapeutics plc (AUTL) Earnings Per Share (EPS)?
The trailing EPS is -$1.11, and the forward EPS is -$0.64.
What is Autolus Therapeutics plc (AUTL) EBITDA?
Autolus Therapeutics plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -33.81 million.
Does Autolus Therapeutics plc (AUTL) pay dividends?
No. Autolus Therapeutics plc does not pay a dividend.
How did Autolus Therapeutics plc (AUTL) perform in its most recent earnings report?
In the last report (June 30, 2026), Autolus Therapeutics plc posted an EPS surprise of 28.57% and a revenue surprise of 15.87%.
What is Autolus Therapeutics plc (AUTL) beta (volatility) score?
Autolus Therapeutics plc has a beta of 1.995, suggesting it is more volatile than the market.
